FDA 483 - WuXi Biologics Ireland Limited - December 16, 2025

Between December 8 and December 16, 2025, the U.S. Food and Drug Administration (FDA) inspected the WuXi Biologics Ireland Limited facility in Dundalk, Ireland. As a drug substance manufacturer, the firm was evaluated for compliance with quality and safety standards. The inspection identified four primary areas of concern. First, the facility used defective equipment, specifically single-use bags that exhibited significant leak rates during critical manufacturing stages. Second, laboratory controls were found inadequate due to high rates of invalid test results for essential quality attributes, suggesting that training efforts have been insufficient. Third, investigators noted discrepancies between manual manufacturing logs and electronic tracking systems, highlighting a lack of consistent documentation. Finally, the facility’s protocols for investigating failed test results were flawed; the current procedure allows staff to dismiss initial test failures and perform retesting without identifying a confirmed root cause. These observations represent preliminary findings rather than a final agency determination. WuXi Biologics is expected to submit a formal response to the FDA detailing their corrective actions or providing explanations for these deficiencies to ensure the facility meets the necessary regulatory requirements for drug production.